Artizan Biosciences Aims to Improve Patient Care Under New President and CEO

Dr. Bridget Martell has been named President and Chief Executive Officer of Artizan Biosciences

FREMONT, CA: “I’m honored to be leading such an exceptional, world-class, and dedicated team at Artizan as we leverage our proprietary platform-based technology to create novel differentiated small-molecule therapeutics to precisely stop microbial-driven dysregulation and inflammation that is central to many serious diseases,” states Dr. Martell. “It’s an exciting time to be part of the Companys’s efforts to enter the clinic with our lead program in inflammatory bowel disease that is supported by our strategic partnerships with Biohaven Pharmaceuticals and Brii Biosciences.” Artizan Biosciences, a biotechnology firm pioneering precision medicine for the microbiome, has hired Bridget Martell, M.A., M.D., as President and Chief Executive Officer. Dr. Martell is an accomplished biopharmaceutical executive with a track record of delivering significant accomplishments in clinical development, medical affairs, and business development across a broad range of therapeutic areas, from first-in-human to licensure and commercialization. She takes up the duties from James (Jimmy) Rosen, M.B.A., M.S.P.H.

“We are delighted to have Dr. Martell join Artizan as she brings a proven track record of developing promising science into therapeutic products that improve patient lives. 

Her bench-to-bedside experience will be extremely valuable to the Company as it works to enter the clinic,” comments Artizans Board of Directors Chairperson Christy Shaffer, Ph.D. “On behalf of the entire board, I would like to extend our gratitude to Jimmy Rosen for his contributions to Artizan. Under his leadership, the Company raised over $22 million, expanded its integrative biology laboratory team and footprint, established our proprietary microbiome system, and secured collaborations with leading biotech companies. We wish him well in his future endeavors.”

Dr. Martell brings a wealth of scientific expertise to her leadership responsibilities and has been instrumental in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilar Ogivri®, as well as secondary indications for Pradaxa® and Sutent®. She has held executive leadership and C-suite positions at companies such as Kura Oncology, where she oversaw the rapid growth of the menin inhibitor program, and Juniper Pharmaceuticals, where she oversaw the development of a novel combined drug/device technology that was out-licensed for $131 million. Dr. Martell is now a member of the Achieve Life Sciences Board of Directors and a Venture Partner at AlleyCorps Healthcare Fund.